loader image
0%

Controlling auto‑immune diseases

Founded on a breakthrough discovery

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.
Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo.
The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

CXCR4 as a master regulator of inflammation

The company is based on the recently published[1],[2] breakthrough discovery of Dr Jean-Philippe Herbeuval team at CNRS and University Paris Descartes. They found that the well-known G protein-coupled receptor (GPCR) chemokine receptor, CXCR4, acts as a master regulator of inflammation via a novel mechanism of action.

This novel mechanism of action, contrary to that of conventional CXCR4 antagonists, allows to control efficiently the production of type 1 interferons by plasmacytoid dendritic cells (pDC) known to play a central role in the inflammatory cascade, positioning CXCR4 as a master regulator of inflammation.  

Erganeo provided initial funding to the project, within an academic setting generate the first chemical series, and proof of concept in auto-immune disease animal models opening the door to the discovery of a brand-new class of drugs to be developed by Ermium.

[1] N Smith et al, Sci. Adv. 2019; 5:eaav9019

[2] Smith et al., Nat Commu, 20178 :14253

Targeted Diseases

Ermium Therapeutics aim is to develop orally available drug candidates for a wide range of auto-immune diseases affecting millions of people worldwide. There are more than 100 auto-immune diseases including :

  • Systemic lupus erythematosus
  • Multiple sclerosis
  • Rheumatoid arthritis
  • Sjögren syndrome
  • Inflammatory bowel diseases

The prevalence of autoimmune diseases corresponds to 7 % of the US population.

Jean-Philippe Herbeuval, PhD

Scientific founder

Dr Jean-Philippe Herbeuval is Director of research at the CNRS, and is currently directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the University Paris Descartes. He has specialized for more than 15 years in the study of pDC modulations and particularly the modulation of such cells by pharmacologic interventions. His research achievements have been awarded in France and also internationally in the USA and is the co-author of 58 peer reviewed articles and 6 patents. 

Joël Crouzet, PhD

CEO

Dr Joël Crouzet is the CEO of Ermium Therapeutics. He has more than 30 years of experience in the Biotech and the Pharma industry. He has been the cofounder and CEO of InnaVirVax, a French biotech that developed a therapy for HIV infection up to phase 2 clinical trial. Joël has had various positions in several biotech companies (Genetica, AP cells, Neurotech and Alfact Innovation) and in the Pharma (Rhone-Poulenc Rorer now part of Sanofi Aventis) and has been involved actively in 5 different drug candidates studied in the clinic. Scientific by training, Joël is a co-author of more than 60 peer reviewed publications.

Investors

Kurma Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions

Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services.

Erganeo is a French investment company specializing in disruptive innovations with a positive impact on our society. Her mission is to accelerate and simplify the associations between Public Research and the industrial world to support an ethical and sustainable progress.

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies.

Some news

Sept 11th 2019
Ermium Therapeutics completes a series A funding of €6.3 million to develop breakthrough auto-immune therapeutics
July 31rst 2019
Ermium execute a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting

Legal notices

Ermium Therapeutics registered under number SIRET 85199803900016, is a simplified stock company.

Located at 16 Boulevard Saint Germain 75005 PARIS and with a registered capital of €1,352, it specializes in research and development in biotechnology (7211Z).

Intellectual property :

This site constitutes a work protected by copyright in force in France. In addition, unless otherwise stated, the intellectual property rights in the documents contained in the site (texts, photographs, images, etc.) and each of the elements created for this site are the exclusive property of Ermium Therapeutics. Reproduction of all elements published on the site Ermium.com is expressly prohibited (article 122.4 of the code of the intellectual property).

Sites linked directly or indirectly to the Ermium.com site are not under its control. Consequently, Ermium Therapeutics assumes no responsibility for the information published on these sites.

Hosting

OVH:
SAS with capital of €10,069,020
RCS Lille Métropole 424,761,419,00045
APE Code 2620Z
VAT number: FR 22 424 761 419
Headquarters: 2 rue Kellermann – 59100 Roubaix – France

Publication Director :
Joel Crouzet

contact@ermium.com

Stages de couture

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Ateliers du dimanche

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Cours enfant

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours réalisation 

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours coupe

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Préparation au C.A.P.

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.